VERA - Chinook Therapeutics: Multiple Shots On Goal For IgAN
Summary
- Shares have risen by 50% since coming public via reverse merger in 2020.
- Lead drug atrasentan has shown promising reductions in proteinuria that exceed approved treatment Tarpeyo.
- Competition in IgAN should not be underestimated from the likes of Travere Therapeutics, Vera Therapeutics and other peers.
- BION-1301 offers them a second shot on goal with superior potency. Key readouts for both assets are approaching in 2023.
- KDNY is a Buy and I suggest accumulating dips to high-teens. Key risks include emerging competition in IgAN as well as disappointing pivotal readout for atrasentan.
For further details see:
Chinook Therapeutics: Multiple Shots On Goal For IgAN